The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2019 | Final phase 2 results of LCL161 for myelofibrosis
Naveen Pemmaraju
• 8 Dec 2019
At the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL, the final results of phase 2 trial of LCL161 for myelofibrosis (MF) were presented by Naveen Pemmaraju, MD, MD Anderson Cancer Center, Houston, TX. Here Dr Pemmaraju discusses the findings from the use of this novel oral SMAC mimetic/IAP antagonist in intermediate to high-risk MF (NCT02098161).
